trial

Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone

NCTId NCT07575516
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 80 (actual)
Sponsored by Hasanuddin University
Primary completion 2026-01-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
80 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2025-10-01
Primary completion
2026-01-30
Eligibility
MALE · 20 Years · 45 Years

Interventions & indications

Drugs
RisperidoneAshwagandha

Sponsors

Hasanuddin UniversityLead Sponsor

Investigators

1
Masnaeni Awaliah, MDPrincipal Investigator

Sites

1 total
Makassar, Indonesia

Linked catalysts

1
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone — primary completion2026-01-30

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE2
Primary Completion Date
2026-01-30
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Ashwagandha
drug
lead_sponsor
Hasanuddin University
company
indication
Neuroinflammatory Diseases
indication
Neuroinflammation
indication
Schizophrenia
indication
investigator
Masnaeni Awaliah, MD
person